Biotech of the Week: ANI Pharmaceuticals, Inc.

Can ANI Pharmaceuticals compete with Teva Pharmaceuticals, Novartis, and the rest of the big generic-drug makers?

Apr 27, 2014 at 2:00PM

ANI Pharmaceuticals (NASDAQ:ANIP) is the biotech of the week on the Fool's weekly show Biotech Banter. Watch the following video, where senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss the generic-drug company that went public last year through a merger with BioSante.

Since then the company acquired some already-approved generic drugs from Teva Pharmaceuticals (NYSE:TEVA) and set up partnerships with Sofgen Pharmaceuticals and Sterling Pharmaceutical Services.

In addition to sales of its generic-drug products, ANI Pharmaceuticals has potential for milestones and royalties from BioSante's legacy programs: a testosterone gel licensed to Teva and a portfolio of cancer vaccines licensed to Aduro BioTech.

The small generic-drug maker might have trouble competing with Teva, Novartis (NYSE:NVS), and the rest of the big boys, but ANI Pharmaceuticals may be able to find a niche and potentially be a takeout target down the road.

The generic-drug industry might be boring, but these industries are set up for incredible growth
Uncover David Gardner's scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly in this this premium report he's making free for you today. Click here now for access.

Brian OrelliMax Macaluso and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information